Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | FOLL12 trial: response-oriented maintenance therapy for advanced follicular lymphoma

Massimo Federico • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma
FOLL12

Massimo Federico, MD, University of Modena and Reggio Emilia, Modena, Italy, discusses response oriented maintenance therapy in advanced follicular lymphoma, explaining the results of the interim analysis of the FOLL12 trial (NCT02063685). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Massimo Federico

Long-term outcomes for patients with PTCL: 10-year follow-up analysis
1:35
Long-term outcomes for patients with PTCL: 10-year follow-up analysis
Massimo Federico • 15 Jun 2023
Early PET-adapted treatment for Hodgkin lymphoma: 10-year follow-up analysis
3:42
Early PET-adapted treatment for Hodgkin lymphoma: 10-year follow-up analysis
Massimo Federico • 15 Jun 2023
The T-cell lymphoma project: prospective data collection changing the world
2:11
The T-cell lymphoma project: prospective data collection changing the world
Massimo Federico • 20 Jun 2019

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Massimo Federico • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Massimo Federico • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Massimo Federico • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Massimo Federico • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals